Role of pharmacists in optimizing the use of anticancer drugs in the clinical setting

Sj, Carolyn

doi:10.2147/iprp.s40428

Cited by 30 publications

(42 citation statements)

References 94 publications

(96 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such collaborations between clinicians and oncology pharmacy specialists (where such are available) will go a long way in ensuring optimum cytotoxic drug procurement, administration, evaluation and monitoring. [ 15 ]…”

Section: Discussionmentioning

confidence: 99%

Wilms′ tumour in African children: Can an institutional approach improve outcome?

Anyanwu¹,

Atanda²,

Atanda³

2015

Afr J Paediatr Surg

View full text Add to dashboard Cite

Background:The poor outcome for patients with Wilms’ tumour (WT) in developing countries has been predicated on late presentation, poverty and low rate of chemotherapeutic access. This study aims to evaluate the effects of an institutionalised approach to improving outcome for patients managed in a tertiary hospital in Nigeria.Materials and Methods:Oncology records of children diagnosed with WT between 2009 and 2013 were analysed for therapy completion and other prognostic parameters. Ensuing data were then compared with those from other centres in Africa.Results:Compared with results from some local and African studies, the therapy completion rate was higher (60%) with a survival rate among this group being between 1 and 4 years. No patient was lost to follow-up because of unavailability or unaffordability of cytotoxic agents.Conclusion:This study shows that an institutionalised approach can help to improve access to anti-cancer drugs, reduce the rate of loss to follow-up and thus improve outcome. There is however need to improve on patient-doctor communication, form support groups and establish a WT registry.

show abstract

Section: Discussionmentioning

confidence: 99%

Wilms′ tumour in African children: Can an institutional approach improve outcome?

Anyanwu¹,

Atanda²,

Atanda³

2015

Afr J Paediatr Surg

View full text Add to dashboard Cite

show abstract

“…35 Given the increasing incidence of cancer, it is expected that more patients will receive oral cancer treatment in the coming decades. 36 In addition, cancer survivors often require ongoing care and support. For many, cancer is now considered a chronic disease, which highlights the importance of long-term medication adherence.…”

Section: Discussionmentioning

confidence: 99%

Geraniin inhibits oral cancer cell migration by suppressing matrix metalloproteinase‐2 activation through the FAK/Src and ERK pathways

Yeh

Hsieh

Yang

et al. 2019

Environmental Toxicology

View full text Add to dashboard Cite

Geraniin has been reported to have numerous biological activities, including antiviral, antihypertensive, antihyperglycaemic, liver protective, antidiabetic, and apoptotic activities. However, the anti‐migration effects of geraniin on oral cancer remain elusive. In this study, we revealed the potential antitumor mechanisms of geraniin through the inhibition of the migration and invasion of human oral cancer cell lines SCC‐9 and SCC‐14. The results of gelatin zymography and Western blot assays revealed that geraniin significantly reduced the activity and expression of matrix metalloproteinase‐2 (MMP‐2) of oral cancer cells in a concentration‐dependent manner. Furthermore, geraniin potently suppressed the phosphorylation of focal adhesion kinase (FAK), Src, and extracellular signal‐regulated kinase (ERK)1/2 but did not affect the phosphorylation of p38 mitogen‐activated protein kinase (MAPK) and c‐Jun N‐terminal kinase 1/2. Moreover, blocking the MAPK/ERK1/2 pathway significantly enhanced the anti‐migration ability of geraniin in oral cancer cells. In conclusion, we demonstrated that geraniin inhibits the motility of SCC‐9 and SCC‐14 cells in vitro through a molecular mechanism that involves the attenuation of MMP‐2 expression and activity mediated by decreased FAK/Src and ERK1/2 pathways.

show abstract

“…The scope of practice document from the Hematology/Oncology Pharmacy Association noted the integral role of hematology/oncology pharmacists in cancer care teams in a variety of roles [ 46 , 47 ]. Common services and care provided by oncology pharmacists include developing therapeutic plans, collaboration with oncologists in medication selection/adjustment, adverse drug reaction prevention and monitoring, laboratory test ordering and monitoring, drug compounding, dispensing, supply management, patient counseling, patient/family and provider education, addressing drug insurance requests, research, and assisting in the development of evidence-based guidelines [ 48 , 49 , 50 , 51 , 52 ].…”

Section: The Oncology Workforcementioning

confidence: 99%

Adherence to Oral Anticancer Medications: Evolving Interprofessional Roles and Pharmacist Workforce Considerations

et al. 2018

View full text Add to dashboard Cite

Interprofessional care is exhibited in outpatient oncology practices where practitioners from a myriad of specialties (e.g., oncology, nursing, pharmacy, health informatics and others) work collectively with patients to enhance therapeutic outcomes and minimize adverse effects. Historically, most ambulatory-based anticancer medication therapies have been administrated in infusion clinics or physician offices. Oral anticancer medications (OAMs) have become increasingly prevalent and preferred by patients for use in residential or other non-clinic settings. Self-administration of OAMs represents a significant shift in the management of cancer care and role responsibilities for patients and clinicians. While patients have a greater sense of empowerment and convenience when taking OAMs, adherence is a greater challenge than with intravenous therapies. This paper proposes use of a qualitative systems evaluation, based on theoretical frameworks for interdisciplinary team collaboration and systems science, to examine the social interactionism involved with the use of intravenous anticancer treatments and OAMs (as treatment technologies) by describing patient, organizational, and social systems considerations in communication, care, control, and context (i.e., Kaplan’s 4Cs). This conceptualization can help the healthcare system prepare for substantial workforce changes in cancer management, including increased utilization of oncology pharmacists.

show abstract

Role of pharmacists in optimizing the use of anticancer drugs in the clinical setting

Cited by 30 publications

References 94 publications

Wilms′ tumour in African children: Can an institutional approach improve outcome?

Wilms′ tumour in African children: Can an institutional approach improve outcome?

Geraniin inhibits oral cancer cell migration by suppressing matrix metalloproteinase‐2 activation through the FAK/Src and ERK pathways

Adherence to Oral Anticancer Medications: Evolving Interprofessional Roles and Pharmacist Workforce Considerations

Contact Info

Product

Resources

About